Relay Therapeutics (RLAY) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last twelve months. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RLAY shares.
View RLAY analyst ratings or view top-rated stocks.

8 brokers have issued 1-year price targets for Relay Therapeutics' stock. Their RLAY share price forecasts range from $12.50 to $46.00. On average, they predict the company's stock price to reach $27.83 in the next year. This suggests a possible upside of 153.0% from the stock's current price.
View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts.

Relay Therapeutics' stock was trading at $14.94 on January 1st, 2023. Since then, RLAY stock has decreased by 26.4% and is now trading at $11.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our RLAY earnings forecast.

Relay Therapeutics, Inc. (NASDAQ:RLAY) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.08. The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.16 million. Relay Therapeutics had a negative net margin of 27,163.46% and a negative trailing twelve-month return on equity of 35.73%. The company's revenue was down 46.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.61) earnings per share.

ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), First Trust NASDAQ BuyWrite Income ETF (FTQI), AI Powered Equity ETF (AIEQ) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).

(RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY."

Relay Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (7.24%), BlackRock Inc. (6.53%), Price T Rowe Associates Inc. MD (5.64%), State Street Corp (4.84%), BVF Inc. IL (2.57%) and ArrowMark Colorado Holdings LLC (2.20%). Insiders that own company stock include Andy Porter, Brian Adams, Donald A Bergstrom, Mark Murcko, Peter Rahmer, Rock Ventures Iii LP Third, Sanjiv Patel and Thomas Catinazzo.
View institutional ownership trends.

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RLAY stock can currently be purchased for approximately $11.00.

Relay Therapeutics (NASDAQ:RLAY) has a market capitalization of $1.34 billion and generates $1.38 million in revenue each year. The company earns $-290,510,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

The company employs 245 workers across the globe.

Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.relaytx.com. The company can be reached via phone at 617-370-8837 or via email at prahmer@relaytx.com.